Literature DB >> 25407449

Dietary fucoidan of Acaudina molpadioides and its enzymatically degraded fragments could prevent intestinal mucositis induced by chemotherapy in mice.

Tao Zuo1, Xuemin Li, Yaoguang Chang, Gaofei Duan, Long Yu, Rong Zheng, Changhu Xue, Qingjuan Tang.   

Abstract

Mucositis is a common problem that results from cancer chemotherapy and is a cause of significant morbidity and occasional mortality. Its prevention and successful treatment can significantly enhance the quality of life of patients and improve their survival. Sea cucumber is a traditional aquatic food that has both nutritional and medicinal value. The polysaccharide fucoidan from the sea cucumber (SC-FUC) has various bioactivities. We examined the protective effect of different molecular weights (MWs 50 kDa-500 kDa) of fucoidan from the sea cucumber, Acaudina molpadioides, in a mouse model of cyclophosphamide (Cy)-induced intestinal mucositis. Results showed that the oral administration of SC-FUC markedly reversed Cy-induced damage in the mice. The sea cucumber fucoidan notably increased the ratio of the length of the intestinal villus to the crypt depth and ameliorated the IFN-γ/IL-4 ratio that signifies Th1/Th2 immune balance. Moreover, all the fucoidans in this study enhanced the expression of IgA by accelerating the expression of IL-6 that is probably combined with IL-10. The differing effects of the varied molecular weights of fucoidan may be due to the difference in the efficiency of absorption. This is a novel study on the potential preventive effects of SC-FUC on intestinal mucositis that may be related to the efficiency of its absorption during digestion. Sea cucumber fucoidan (SC-FUC) may be used as a potential food supplement to prevent chemotherapeutic mucositis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25407449     DOI: 10.1039/c4fo00567h

Source DB:  PubMed          Journal:  Food Funct        ISSN: 2042-6496            Impact factor:   5.396


  12 in total

Review 1.  The pathogenesis of mucositis: updated perspectives and emerging targets.

Authors:  J Bowen; N Al-Dasooqi; P Bossi; H Wardill; Y Van Sebille; A Al-Azri; E Bateman; M E Correa; J Raber-Durlacher; A Kandwal; B Mayo; R G Nair; A Stringer; K Ten Bohmer; D Thorpe; R V Lalla; S Sonis; K Cheng; S Elad
Journal:  Support Care Cancer       Date:  2019-07-08       Impact factor: 3.603

2.  Protective effect of homogeneous polysaccharides of Wuguchong (HPW) on intestinal mucositis induced by 5-fluorouracil in mice.

Authors:  Peng Shi; Tianqi Zhao; Wendong Wang; Fangli Peng; Ting Wang; Yong Jia; Linxuan Zou; Peng Wang; Simengge Yang; Yue Fan; Junwei Zong; Xueling Qu; Shouyu Wang
Journal:  Nutr Metab (Lond)       Date:  2022-05-18       Impact factor: 4.654

Review 3.  Oral Mucositis: An Update on Innate Immunity and New Interventional Targets.

Authors:  C Chen; Q Zhang; W Yu; B Chang; A D Le
Journal:  J Dent Res       Date:  2020-06-01       Impact factor: 8.924

4.  Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo.

Authors:  Farzaneh Atashrazm; Ray M Lowenthal; Joanne L Dickinson; Adele F Holloway; Gregory M Woods
Journal:  Oncotarget       Date:  2016-07-19

5.  Anti-Oxidative and Immuno-Protective Effect of Camel Milk on Radiation-Induced Intestinal Injury in C57BL/6 J Mice.

Authors:  Yu-Zhong Chen; Chao Li; Jia Gu; Si-Chen Lv; Jia-Ying Song; Zhi-Bing Tang; Guang-Xin Duan; Li-Qiang Qin; Lin Zhao; Jia-Ying Xu
Journal:  Dose Response       Date:  2021-03-30       Impact factor: 2.658

Review 6.  Fucoidans and Bowel Health.

Authors:  Jin-Young Yang; Sun Young Lim
Journal:  Mar Drugs       Date:  2021-07-30       Impact factor: 5.118

Review 7.  Therapies from Fucoidan: An Update.

Authors:  Janet Helen Fitton; Damien N Stringer; Samuel S Karpiniec
Journal:  Mar Drugs       Date:  2015-09-16       Impact factor: 5.118

8.  Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial.

Authors:  Hsiang-Lin Tsai; Chi-Jung Tai; Ching-Wen Huang; Fang-Rong Chang; Jaw-Yuan Wang
Journal:  Mar Drugs       Date:  2017-04-21       Impact factor: 5.118

9.  Fucoidan Supplementation Restores Fecal Lysozyme Concentrations in High-Performance Athletes: A Pilot Study.

Authors:  Amanda J Cox; Allan W Cripps; Phillipa A Taylor; J Helen Fitton; Nicholas P West
Journal:  Mar Drugs       Date:  2020-08-04       Impact factor: 5.118

10.  Effects of Polysaccharides From Auricularia auricula on the Immuno-Stimulatory Activity and Gut Microbiota in Immunosuppressed Mice Induced by Cyclophosphamide.

Authors:  Xianghui Kong; Weiwen Duan; Dingjin Li; Xiaoxian Tang; Zhenhua Duan
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.